Simon P. Kim, MD, MPH

Articles by Simon P. Kim, MD, MPH

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

BySimon P. Kim, MD, MPH,Cary P. Gross, MD,Quoc-Dien Trinh, MD,Marc C. Smaldone, MD, MSHP,R. Houston Thompson, MD,Sarah P. Psutka, MD,Holly Van Houten, BA,Leona C. Han, BA,Robert Abouassaly, MD

February 12th 2016

Study investigate the economic burden from the total costs, private insurance reimbursement, and out-of-pocket costs for oral TKI agents among metastatic RCC patients.

Latest Updated Articles

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma
Published: February 12th 2016 | Updated:

Simon P. Kim, MD, MPH

Articles by Simon P. Kim, MD, MPH

Economic Burden of Oral Tyrosine Kinase Inhibitors Among Privately Insured Patients Diagnosed With Metastatic Renal Cell Carcinoma

Latest Updated Articles

Trending on Pharmacy Times

Therapeutic Cancer Vaccines: Are We There Yet?

Transforming HER2+ Metastatic Breast Cancer Treatment With Targeted ADC Therapy

Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy

Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC

Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer